Displaying 1 - 10 of 324
Immune effector cell-associated neurotoxicity syndrome (ICANS)
Updated:
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a side effect that can happen after some forms of immunotherapy treatment. It may cause you to experience serious neurological symptoms.
Treatment and side effects
Myelofibrosis (MF) therapies: From palliation to disease modification - myeloproliferative neoplasms (MPN) conference 2025
Updated:
Dr. Vikas Gupta, Hematologist at the Princess Margaret Cancer Centre in Toronto, reviewed Myelofibrosis (MF) and the evolution in diagnosis, treatment options and aspects of follow-up care in this 1-hour webcast as part of MPN Conference 2025.
Myeloproliferative neoplasms
Preparing for Treatment with Shae-Lynn
Updated:
After being diagnosed with leukemia at 21 years old, Shae-Lynn Way shares her experience with shifting her mindset while preparing for a second stem cell transplant after her leukemia returned.
Leukemia, Treatment and side effects
Understanding polycythemia vera (PV): Diagnosis, treatments and follow-up care - myeloproliferative neoplasms (MPN) conference 2025
Updated:
In this 1-hour live webcast, Dr. Sonia Cerquozzi, hematologist at the Tom Baker Cancer Center and Peter Lougheed Centre in Calgary, reviews PV, a type of MPN - its diagnosis, treatment options and aspects of follow-up care.
Myeloproliferative neoplasms
Understanding essential thrombocythemia (ET): Diagnosis, treatments and follow-up care: MPN conference 2025
Updated:
In this 1-hour webcast, Dr. Lynda Foltz, University of British Columbia, will review this type of myeloproliferative neoplasm (MPN): its diagnosis, treatment options, and aspects of follow-up care.) People with ET have too many platelets, a type of blood cell. Too many…
Myeloproliferative neoplasms
Évolution des thérapies dans la myélofibrose (MF) : Amélioration des traitements et de la prise en charge
Updated:
Dans cette webdiffusion, le Dr Pierre Villeneuve, hématologue à l’Hôpital d’Ottawa, a passé en revue la MF et l’évolution au fil du temps du diagnostic, des options de traitement et des aspects des soins de suivi.
Myeloproliferative neoplasms
Chronic Lymphocytic Leukemia (CLL) Treatment Discussion Guide
Updated:
Beyond active surveillance (the ‘watch and wait approach’) there are several CLL treatments to consider. Each treatment has different features and side effects. It is important to be comfortable with the CLL treatment you choose.
Leukemia
Diffuse Large B-Cell Lymphoma (DLBCL)
Updated:
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). DLBCL is fast-growing (aggressive) but treatable. It most often appears in older adults but can appear at any age.
Lymphoma
Cutaneous T-cell Lymphoma (CTCL)
Updated:
Cutaneous T-cell lymphoma (CTCL) is a slow-growing (indolent) subtype of non-Hodgkin lymphoma (NHL). CTCL is rare, representing 4% of NHL cases. It starts in white blood cells (lymphocytes) that reside in the skin, called T-cells.
Lymphoma
Understanding mantle cell lymphoma (MCL)
Updated:
Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma. It is a blood cancer of the B-lymphocytes (type of white blood cell that fights infections) found in the bone marrow. Learn more about MCL in this animated video.
Lymphoma